The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant

Vaccine

Volumn 20, Issue 13-14, 2002, Pages 1733-1740

  Choi, Anthony H ^a   McNeal, Monica M ^a   Flint, Jason A ^a   Basu, Mitali ^a   Lycke, Nils Y ^c   Clements, John D ^d   Bean, Judy A ^b   Davis, Heather L ^e   McCluskie, Michael J ^e   VanCott, John L ^a   Ward, Richard L ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d TULANE UNIVERSITY MEDICAL CENTER   (United States)

^e Coley Pharmaceutical Group ^*  (Canada)

Author keywords

Rotavirus; Subunit; Vaccine

Indexed keywords

ADJUMER; BACTERIAL TOXIN; CHIMERIC PROTEIN; CHOLERA TOXIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; PROTEIN VP6; QS 21; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; FEMALE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROVOCATION TEST; ROTAVIRUS; TH2 CELL; VIRUS INFECTION; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BACTERIAL TOXINS; CAPSID; CAPSID PROTEINS; CHOLERA TOXIN; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; OLIGODEOXYRIBONUCLEOTIDES; RECOMBINANT FUSION PROTEINS; ROTAVIRUS; ROTAVIRUS INFECTIONS; TH1 CELLS; TH2 CELLS; VIRAL VACCINES;

EID: 0037086580     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00043-9     Document Type: Article

References (32)

1. Rotavirus vaccines
2. Rotavirus intussusception investigation team: Intussusception among infants given an oral rotavirus vaccine
3. Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein
4. Functional mapping of protective domains and epitopes in the rotavirus VP6 protein
5. Comparison of the rotavirus gene 6 from different species by sequence analysis and localization of subgroup-specific epitopes using site-directed mutagenesis
6. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
7. Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B sub-unit vaccine: Results of the initial evaluation in children: PRIDE Study Group
8. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues
9. Adjuvants in perspective
10. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase
11. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin
12. Genetically engineered non-toxic vaccine adjuvant that combines B-cell targeting with immunomodulation by cholera toxin A1 subunit
13. The ADP-ribosylating CTA1-DD adjuvant enhances T-cell-dependent and independent responses by direct action on B-cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects
14. Poly[(dicarboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine
15. Structural and immunological characterization of the vaccine adjuvant QS-21
16. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
17. CpG DNA as mucosal adjuvant
18. Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants
19. Active protection against rotavirus infection of mice following intraperitoneal immunization
20. Development of an adult mouse model for studies on protection against rotavirus
21. Effects of different adjuvants on rotavirus antibody responses and protection in mice following intramuscular immunization with inactivated rotavirus
22. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
23. Particle bombardment-mediated DNA vaccination with rotavirus VP6 induces high levels of serum rotavirus IgG but fails to protect mice against challenge
24. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells
25. Broadening the approaches to developing more effective vaccines
26. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system
27. Antibody-dependent and -independent protection following intranasal immunization of mice with rotavirus particles
28. Kinetics of acid-mediated disassembly of the B subunit pentamer of Escherichia coli heat-labile enterotoxin: Molecular basis of pH stability
29. Mutations in the A subunit affect yield, stability, and protease sensitivity of non-toxic derivatives of heat-labile enterotoxin
30. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity
31. CD4 T-cells are the only lymphocytes needed to elicit protection of mice against rotavirus shedding following intranasal immunization with a chimeric VP6 protein